ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Immmusafe website is back on line!…$$$

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Aug 17, 2021 8:37am

127 Views

Post# 33715861

RE:Immmusafe website is back on line!…$$$

However, we keep on funding this joint venture until the operation is cash flow positive !!!
So this may take a while before we start seeing benefits from it. Does anyone see this to be any different?

Reference MD&A:
"In August 2020, the Company entered into an agreement with BC Neuroimmunology Lab Inc.
(BCNI) on a 50/50 basis to develop diagnostics assays as a joint operation. The Company has
agreed fund the equally the operating costs associated not to exceed $25,000 per month with the Company’s share being $12,500 until the joint operation is cashflow positive." (bolding added)

G1945V

<< Previous

Bullboard Posts

Next >>

How to trade on the stock market: A beginner’s guide